Table 2.
Distribution of retrospectively reported ADRs according to their suspected associated antiretroviral drugs in three HIV cohorts from the IeDEA West Africa collaboration, Abidjan, 2008.
| Antiretroviral drugs(s) withdrawn
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Stavudine | Nevirapine | Zidovudine | Efavirenz | Indinavir | Stavudine+Nevirapine | Zidovudine+Lamivudine | Other drugs* | Total† | |
| ADR retrospectively identified | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
| Peripheral neuropathy | 57 (46.4) | 19 (15.4) | 8 (6.5) | 10 (8.1) | 5 (4.1) | 8 (6.5) | 3 (2.4) | 13 (10.6) | 123 (100) |
| Cutaneous reaction | 19 (43.2) | 2 (4.5) | 4 (9.1) | 4 (9.1) | 11 (25.0) | 3 (6.8) | 0 (0.0) | 1 (2.3) | 44 (100) |
| Hematologic disorders | 12 (60.0) | 0 (0.0) | 3 (15.0) | 2 (10.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 1 (5.0) | 20 (100) |
| Lipodystrophy | 7 (36.8) | 2 (10.5) | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) | 3 (15.8) | 1 (5.3) | 19 (100) |
| Central nervous disorders | 7 (38.9) | 5 (27.8) | 3 (16.7) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (11.0) | 18 (100) |
| Gastrointestinal disorders | 6 (33.2) | 3 (16.7) | 5 (27.8) | 3 (16.7) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 18 (100) |
| Hepatic toxicity | 5 (50.0) | 1 (10.0) | 2 (20.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 10 (100) |
| Cardiac toxicity | 5 (83.3) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (100) |
| Other ADRs‡ | 6 (60.0) | 2 (20.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (100) |
|
| |||||||||
| Total∫ | 124/3323 | 34/2488 | 29/1831 | 25/2177 | 17/253 | 12/2374 | 8/1792 | 19* | 268/5252 |
ART: Antiretroviral treatment. ADR: Adverse Drug Reaction.
Other drug(s) withdrawn: 7/2374 stavudine+lamivudine+nevirapine, 5/775 stavudine+efavirenz, 3/18 abacavir+didanosine, 2/3268stavudine+lamivudine, 2/88 abacavir.
Total number of withdrawn drugs: 268 of the 273 ADR-related treatment modifications for which the antiretroviral drug(s) withdrawn were notified in the medical charts.
Other ADRs: lactic acidosis, nephrotic syndrome, chest tightness, ocular lesion, diffuse pain.
total number of withdrawn drug(s)/total number of patient exposed to the antiretroviral drug(s) withdrawn, as multiple exposure to antiretroviral drugs is likely, the sum of these denominators is not equal to the total number of patients exposed.